Oral Graft-Versus-Host Disease

Kuten‐Shorrer, Michal; Woo, Sook‐Bin; Treister, Nathaniel S.

doi:10.1016/j.cden.2013.12.007

Cited by 46 publications

(51 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinically aGVHD is characterized by strong inflammatory features and it is diagnosed by presence of diffuse maculopapilar rash, erythroderma, nausea, vomiting, anorexia, profuse diarrhea, ileus or cholestatic hepatitis, and it is considered the major cause of early lethality [3,5,11]. Normally, skin, liver and/or digestive tract are targets of aGVHD, however cGVHD is characterized by selective damage to the skin and mucosa, hair and/or nails, eyes, liver, lungs, gastrointestinal tract and muscle fasciae [7,8].…”

Section: Acute Gvhd (Agvhd)mentioning

confidence: 99%

“…The major risk factor for GVHD development is human leukocyte antigens (HLA) disparity [5]. Other risk factors associated with cGVHD include Peripheral blood stem cell transplantation (PBSCT); increasing CD3 (T cell) dose in the graft; increased donor or recipient age; use of an unrelated donor; different gender donor/recipient combination; total body irradiation (TBI); diagnosis of chronic mielogenous leukemia or myelodysplastic syndrome and preceding history of aGVHD [3].…”

Section: Chronic Gvhd (Cgvhd)mentioning

confidence: 99%

“…The first Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) was performed in 1957 to treat end-stage leukemia [1], and it has seen a steady increase in the overall success and applicability to treat a wide range of malignancies, including: neoplastic and nonneoplastic hematologic disease and immune deficiency states, and autoimmune disease [2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

“…In 1966, it was outlined the 3 fundamental requirements for GVHD: the graft must contain immunological competent cells; the host must express tissue antigens that seem foreign to the graft (antigenic mismatch); the host must be incapable of rejecting the donor graft (immune compromise) [3,5]. This disease is mediated by autoreactive T lymphocytes that infiltrate and attack various target organs and tissues, including oral mucosa and salivary glands, leading to salivary hypofunction and oral damage [7,9].…”

Section: Introductionmentioning

confidence: 99%

“…Traditionally, when it targets the immune system, by definition, if seen before Day +100 it is called as acute GVHD (aGVHD), but if it occurs after day 100 it is defined chronic GVHD, however, according to NIH Consensus criteria it is recommended to classify GVHD based on characteristic symptoms and signs rather than a rigid temporal definition [2,3,5,8,10].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Oral chronic graft-versus-host disease: A short review

Hsieh¹,

Souza²,

Paula³

et al. 2016

Trends in Transplant

View full text Add to dashboard Cite

Allogeneic Hematopoietic Steam Cell Transplantation (allo-HSCT) treat a wide range of malignancies, including: neoplastic and non-neoplastic hematologic disease and immune deficiency states, and autoimmune disease. Chronic Graft-versus-host disease (cGVHD) is a major late complication of allo-HSCT, representing a clinical syndrome characterized by complex allogeneic and autoimmune dysregulation of the immune system, leading cause of non-relapse-related morbility and mortality among long-term transplant survivors. The oral cavity is frequently involved, as the second most common site involved after skin due to HSCT.The spectrum of clinical manifestation and histopathological characteristics of oral cGVHD are similar to several autoimmune conditions including Sjögren syndrome, oral lichen planus and scleroderma.Ancillary therapy is used for symptomatic oral mucosal or erythematous or ulcerative disease in GVHD treatment by using routine systemic drugs, several topical treatments as corticosteroids, non-corticosteroids, immunosuppressants, and phototherapy. For affected salivary glands, artificial saliva or saliva stimulators are commonly used to relief the xerostomia symptoms.

show abstract

Section: Acute Gvhd (Agvhd)mentioning

confidence: 99%

Section: Chronic Gvhd (Cgvhd)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Oral chronic graft-versus-host disease: A short review

Hsieh¹,

Souza²,

Paula³

et al. 2016

Trends in Transplant

View full text Add to dashboard Cite

show abstract

Dermatoses of the Oral Cavity and Lips

Scully¹

2016

Rook's Textbook of Dermatology, Ninth Edition

View full text Add to dashboard Cite

Oral and labial lesions are usually the result of local disease but may be the early signs of systemic disease, including dermatological disorders, and in some instances may cause the main symptoms. This chapter mainly discusses disorders of the periodontal and mucosal tissues that may be related to skin disease and that may present at a dermatology clinic. It should be borne in mind that the professionals most competent in diagnosing and treating oral diseases are those with formal dental training and who are therefore in a position to understand the full complexities of the region. This chapter is divided into a brief discussion of the biology of the mouth, an overview of the more common signs and symptoms affecting specific oral tissues, discussion of the disorders of the oral mucosa of most relevance to dermatology and a tabulated review of oral manifestations of systemic diseases. Only the more classic oral lesions are illustrated. For reasons of space restrictions, diseases affecting the teeth, salivary glands, jaws or temporomandibular joints are not discussed in any depth.

show abstract

Oral Complications of Cancer and Their Treatment

Sonis

Yuan

2017

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview The mouth is a frequent site of direct and indirect adverse side effects of cancer therapy. In myelosuppressed patients, its diverse microbiota makes the oral cavity both a site of local infection and a potential source of bacteremias and sepsis. While about half of all patients being treated with chemotherapy or radiation therapy will develop some form of oral toxicity or infection, almost every patient receiving an aggressive myeloablative regimen or local radiotherapy to the head and neck manifests acute and chronic toxicities. The diversity of the tissues found in and around the mouth—keratinized and nonkeratinized mucosa, bone, salivary glands, and teeth—contributes to the range of susceptibility, acuity, and clinical implications of regimen‐related oral complications. In almost all instances, precancer treatment elimination or control of existing oral diseases and aggressive management of oral health during cancer therapy favorably impacts outcomes.

show abstract

Oral Graft-Versus-Host Disease

Cited by 46 publications

References 81 publications

Oral chronic graft-versus-host disease: A short review

Oral chronic graft-versus-host disease: A short review

Dermatoses of the Oral Cavity and Lips

Oral Complications of Cancer and Their Treatment

Contact Info

Product

Resources

About